Originally, when the novel coronavirus first became a thing, Novavax (NASDAQ:NVAX) showed great promise. While other vaccine developers were experimenting with pioneering nucleic-acid-based technologies, Novavax went with a subunit mechanism, a proven approach used in the hepatitis B vaccine. Theoretically, that should have been great news for NVAX stock and it was, at least for a while.
Source: Ascannio/Shutterstock.com
No matter how you look at it, Novavax is a Covid-19 winner. Prior to the pandemic, the company was staring at a complete implosion, having failed to deliver....More>>>